The existing work examined the potential of using ARV-825 and ABBV-744 to raise the effectiveness of tamoxifen or fulvestrant additionally palbociclib. ARV-825 was effective in the two p53 wild-sort (WT) breast tumor cells As well as in cells missing functional p53 either by itself or in combination with tamoxifen, though https://abbv-744-in-the-treatment69135.aboutyoublog.com/34556611/a-review-of-abbv-744-in-combination-with-immunotherapy